- Objective of a sales turnaround after the CMDS acquisition achieved
- Growth in revenue in the fourth quarter for all activities and all geographic regions
Villepinte, February 15, 2017 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is reporting revenue of €775.8 million at December 31, 2016, up 58.7% from 2015.
This change includes a negative currency effect of €13.0 million. At constant exchange rates, and on a like-for-like basis (vs. the 2015 pro forma revenue), the Group posted stable sales of €788.8 million (-0.1%) in line with the guidance. The main challenge in 2016 was in fact to successfully turn around the declining sales of the activity bought at the end of 2015.
The 7.1% growth in the fourth quarter reflects this trend reversal and proves the successful integration of the former CMDS activities. This performance allows the Group to approach the year 2017 with confidence, a year that should see growth in celebration of the Group's 90th birthday.
Consolidated Group revenue at current exchange rates (IFRS)
